An interventional study of Intensive guideline algorithm implementation and Conventional guideline algorithm implementation in Type 2 Diabetes, Cardiovascular Complication and Diabetic Kidney Disease, sponsored by Shanghai Zhongshan Hospital. Recruiting at 13 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai Zhongshan Hospital.
Among the 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 with no phase, and was the 9th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,600 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 120 across the 13 interventional studies, 160 across the 2 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
3 of the studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05349955Shanghai Zhongshan HospitalEffects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community | 2026-11-30 |
| NCT07118475Shanghai Zhongshan HospitalAutologous Islet Transplantation for Diabetes | 2027-05-30 |
| NCT07307235Shanghai Zhongshan HospitalEfficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Effects and Safety of Diabetic GUideline Algorithm Implementation in the Community (GUARD-Community) study is a 2-arm, cluster-randomized control trial to evaluate the effect and safety of guideline algorithm intervention performed by primary care physicians on cardiovascular and renal outcomes in elderly patients with high risk in community.
Diabetes is an important public health concern. Elderly diabetic patients are characterized by a long duration and complications, including chronic kidney disease and/or cardiovascular disease. In the past 30 years, the guidelines of CDS, EASD or ADA have been frequently updated. The latest guideline on pharmacological algorithm recommend that patients with cardiovascular, renal disease or very high/high CV risk patients should be treated with anti-diabetic drugs presenting target organ protection, including SGLT2i and GLP1RA. And the guideline recommend comprehensive control of the cardiovascular risk factors, such as hypertension and dyslipidemia.
This GUARD-Community study is a community based cluster-randomized controlled trial and will enroll 5600 or more participants in more than 120 clusters aged ≥ 65 years with T2DM and complicated with high/very high cardiovascular risk factors . The trial will evaluate the the effects and safety of intensive "Guideline" algorithm implementation on CVD and renal outcomes. The primary hypothesis is that guideline algorithm intervention implemented by primary care physicians will significantly reduce the risk of 4-point MACE (comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization of heart failure) rates. In Phase 1 study, the control of blood sugar, blood pressure and lipids will be evaluated at 18 months after intervention. In Phase 2 study, the CVD and renal outcomes will be evaluated at 3 years. The study will last for 4 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SGLT2i or GLP-1RA recommended in priority in subjects at very high/high CV risk. The targets of intervention will be achieved at HbA1C \<7%, blood pressure \<130/80mmHg, LDL-c\<1.8mmol/L at very high CV risk or \<2.6mmol/L at high CV risk patients, antiplatelet as secondary prevention of ASCVD.
Other: Intensive guideline algorithm implementation
Treatment based on the current approaches implemented by local physicians(primary care physicians). Guideline based education and consults will be conducted to primary care physicians.
Other: Conventional guideline algorithm implementation
Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg, LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
Primary Outcome of Phase 1: Comprehensive management effect of various cardiovascular risk factors in T2D,meeting control targets for a combination of A1c, BP, LDL-C.
The proportion of participants with HbA1C\<7.0%, blood pressure\< 130/80 mm Hg,LDL-c\<1.8mmol/L at very high CV risk or \<2.6mmol/L at high CV risk.
Time frame: 18 months since randomization
Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure.
Time to occurrence of cardiovascular and cerebrovascular death, non-fatal myocardial infarction, non-fatal Stroke, hospitalization for heart failure.
Time frame: 3 years since randomization
Secondary Outcome of Phase 1: Glycemic control rate
The proportion of participants with tight glucose control, targeting HbA1c \<7.0%
Time frame: 18 months since randomization
Secondary Outcome of Phase 1: Mean HbA1C changes
Mean HbA1C changes of participants
Time frame: 18 months since randomization
Secondary Outcome of Phase 1: Mean systolic and diastolic pressure changes
Mean systolic and diastolic pressure changes of participants
Time frame: 18 months since randomization
Secondary Outcome of Phase 1: Mean LDL-c changes
Mean LDL-c changes of participants
Time frame: 18 months since randomization
Secondary Outcome of Phase 1: Adherence to guideline algorithm medication recommendation rate
Use electronic medical recorded prescription and questionnaires to assess the proportion of participants who adhere to guideline recommended medication
Time frame: 18 months since randomization
Secondary Outcome of Phase 2: Incident or worsening nephropathy
Time to composite of incident macroalbuminuria (UACR \>300 mg/g), a sustained decline in eGFR (decrease in the eGFR of 30% or more to a value of less than 60 when baseline ≥60ml per minute per 1.73 m2, decrease in the eGFR of 50% or more when baseline \<60ml per minute per 1.73 m2)from baseline, or chronic renal replacement therapy, or renal death.
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Cardiorenal composite endpoint
Time to eGFR (CKD-EPI formula) decrease, renal replacement therapy, renal or cardiovascular death
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: 3P MACE
Time to events occurence: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: New onset of macroalbuminuria.
Time to UACR\>300mg/g
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Changes of myocardial ischemia in electrocardiogram (ECG)
Participants number of ECG ischemia demonstration occurence: ST-T segment depression more than 0.1mv in two adjacent leads of ECG compared with baseline, poor R wave progression.
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: New onset of albuminuria
Time to UACR increase from \<30mg/g to ≥30mg/g
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Albuminuria progression
Time to albuminuria progression: UACR increased by ≥30% and grade progression (ie, from normal to micro or macro, or from micro to macro)
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Albuminuria regression
Time to albuminuria regression: UACR grade regression(ie, from macro to micro or normal, or from micro to normal), and the UACR value decreases by more than or equal to 30%
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Changes in the ratio of patients with normal or abnormal urine protein at the end of the study
Rate change of normal or abnormal UACR. Normal means UACR\<30mg/g. Abnormal means UACR≥30mg/g
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Slope of eGFR decline
Decrease of the eGFR over time
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Retinopathy changes
Occurrence or regression of retinopathy(ETDRS-DRSS)
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Body weight change
Absolute weight change and the percentage change of body weight
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Changes of fatty liver prevalence
Rate change of fatty liver.
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Changes in beta-cell function
Absolute change assessed by HOMA2-%β method
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: Changes in cognitive function
Improvement or progression of cognitive function: The Mini-CogTM scale
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: The FRAIL scale
Changes of the simple frailty questionnaire score
Time frame: 3 years since randomization
Secondary Outcome of Phase 2: All-cause death
Time to the death due to any cause
Time frame: 3 years since randomization
Health Economics Indicators
Cost-effectiveness analysis: quantification of Incremental Cost Ratio Life Cycle (ICER) and Quality Adjusted Years (QALYs)
Time frame: 3 years since randomization
Changes in cardiovascular risk indicators
Framingham score
Time frame: 3 years since randomization
Serology and urine testing
Biomarkers associated with diagnosis or prognosis: using "omics" screening.
Time frame: 3 years since randomization
Genomics testing
Gene polymorphism testing for drug response or prognosis: using genome-wide association study(GWAS) screening.
Time frame: 3 years since randomization
The time rate of glycemic target range
Continous glucose monitor detection
Time frame: 3 years since randomization
Plan to share: No — The data will be available from the principle investigator on reasonable request.
Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 48 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.